With Novo CEO on the hot seat at Senate hearing, PBMs and insurance concerns get the spotlight
When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit managers (PBMs) often commands at least some of the attention. | At the Senate committee hearing on Novo Nordisk's prices for Ozempic and Wegovy,
The PBMs say out-of-pocket insulin costs have fallen sharply since 2019. The Pharmaceutical Care Management Association, ...
FTC files lawsuit against top PBMs and GPOs for alleged anticompetitive practices in inflating insulin prices. Learn about the allegations and responses.
In a move to address escalating insulin prices, the Federal Trade Commission (FTC) has initiated action against the three ...
Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...
U.S. Senator Bernie Sanders announced that pharmacy benefit managers have agreed to expand coverage for Novo Nordisk's ...
No, if Novo Nordisk lowered their list price for Ozempic and Wegovy tomorrow to a price that was the same or lower than current net cost, that change by itself would not result in less favorable ...
The Federal Trade Commission has accused three major pharmacy benefit managers of inflating insulin prices, the agency said ...
California lawmakers have sent a bill to Gov. Gavin Newsom that aims to rein in the PBMs they say drive up costs and limit ...
The US Federal Trade Commission said that CVS Health's Caremark, Cigna's Express Scripts, and UnitedHealth Group's Optum ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback